can glp 1 hurt your kidneys Glucagon-like Peptide Receptor Agonists and Kidney Outcomes in the Era of Personalized Medicine: Focus on Albuminuria GLP-1 agonists in the treatment
Description
Retrospectively registered, 8 October 2021.
Prescribing GLP-1 drugs to treat adolescents with obesity involves some unique considerations, according to experts, including many unknowns about the potential long-term health impacts both positive and negative in patients so young. We dont know if theres a differential effect of starting the medication at a younger age versus an older age, said []
Its primary outcomes measure is time to first occurrence of any component event of a composite endpoint comprising all-cause death, non-fatal myocardial infarction, non-fatal stroke, coronary revascularization, or heart failure events that result in hospitalization or urgent hospital visits
It is a big indication (5% of western population) and growing rapidly
As GLP-1 therapies continue to redefine chronic care, dependable containment becomes an essential part of treatment success
